ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.

Vivek Subbiah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.